DeepMed Research

NovoCure Ltd.

🇯🇪Jersey

Country: 🇯🇪Jersey

Ownership: Public

Established: 2000-01-01

Employees: 1.4K

Market Cap: -

Website: http://www.novocure.com

Clinical Trials

TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)

Recruiting

Conditions: Glioblastoma

First Posted Date: 2025-04-11

Last Posted Date: 2025-04-11

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 430

Registration Number: NCT06924099

Locations: 🇫🇷
Ch Regional Orleans, Orléans, France
🇫🇷
Hopital Saint Louis, Paris, France
🇫🇷
Institut Sainte-Catherine, Avignon, France

and more 21 locations

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Device: Tumor Treating Fields
Drug: Atezolizumab
Drug: Gemcitabine
Drug: nab-paclitaxel

First Posted Date: 2024-04-29

Last Posted Date: 2025-04-30

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 84

Registration Number: NCT06390059

Locations: 🇩🇪
Asklepios Hospital Altona, Hamburg, Germany
🇩🇪
University Hospital Ulm, Ulm, Germany
🇪🇸
University General Hospital Gregorio Maranon, Madrid, Spain

and more 12 locations

TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study

Recruiting

Conditions: Glioblastoma

Interventions: Device: TTFields

First Posted Date: 2021-01-22

Last Posted Date: 2023-01-10

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 500

Registration Number: NCT04717739

Locations: 🇩🇪
Universitätsklinikum Augsburg (AöR), Augsburg, Germany
🇩🇪
Klinikum Chemnitz, Chemnitz, Germany
🇩🇪
Universitätsklinikum des Saarlandes, Homburg, Germany

and more 33 locations

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Not Applicable

Active, not recruiting

Conditions: Glioblastoma Multiforme

Interventions: Device: Optune®

First Posted Date: 2020-07-15

Last Posted Date: 2024-11-14

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 982

Registration Number: NCT04471844

Locations: 🇺🇸
Mary Bird Cancer Center Neuromedical Center, Baton Rouge, Louisiana, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸
Neuroscience Center, Philadelphia - University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 128 locations

Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Not Applicable

Completed

Conditions: Gastric Cancer
GastroEsophageal Cancer

Interventions: Device: NovoTTF-100L(P)
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Trastuzumab

First Posted Date: 2020-02-24

Last Posted Date: 2024-11-14

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 28

Registration Number: NCT04281576

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Phase 3

Completed

Conditions: Ovarian Cancer

Interventions: Device: NovoTTF-100L(O)
Drug: Paclitaxel

First Posted Date: 2019-05-07

Last Posted Date: 2024-03-29

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 540

Registration Number: NCT03940196

Locations: 🇺🇸
Center of Hope at Renown Medical Center, Reno, Nevada, United States
🇺🇸
UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Minnesota Oncology Hematology, PA, Saint Paul, Minnesota, United States

and more 104 locations

TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM

Not Applicable

Conditions: Glioblastoma Multiforme

Interventions: Device: NovoTTF-200A
Radiation: Radiotherapy
Drug: Temozolomide

First Posted Date: 2018-12-19

Last Posted Date: 2018-12-20

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 10

Registration Number: NCT03780569

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Device: NovoTTF-100L(P) device
Drug: Sorafenib

First Posted Date: 2018-07-31

Last Posted Date: 2024-11-14

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 25

Registration Number: NCT03606590

Locations: 🇨🇿
University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc, Czechia
🇩🇪
Ulm University Hospital, Ulm, Germany
🇫🇷
CHU de Nantes, Nantes Cedex 01, France

and more 5 locations

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Phase 3

Completed

Conditions: Pancreas Adenocarcinoma

Interventions: Device: NovoTTF-200T
Drug: Gemcitabine
Drug: nab paclitaxel

First Posted Date: 2017-12-19

Last Posted Date: 2024-10-31

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 571

Registration Number: NCT03377491

Locations: 🇦🇺
St. John of God Murdoch Hospital, Murdoch, Western Australia, Australia
🇦🇺
Monash Medical Centre, Clayton, Australia
🇦🇺
Sydney Adventist Hospital, Wahroonga, Australia

and more 196 locations

TTFields In GErmany in Routine Clinical Care

Conditions: Glioblastoma

Interventions: Device: TTFields

First Posted Date: 2017-08-22

Last Posted Date: 2021-01-28

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 710

Registration Number: NCT03258021

Locations: 🇩🇪
Clinical center Aschaffenburg-Alzenau, Aschaffenburg, Bavaria, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy